Lenalidomide Capsule
Product Images NDC 70377-050

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 70377-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc.,, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-28-counts (10mg 28 Counts)

Packaging label for Lenalidomide Capsules 10 mg by Biocon Pharma Inc. The label shows 28 capsules with a child-resistant package. It includes storage instructions, a birth defect warning, and manufacturer information for Biocon Pharma Limited, Bengaluru, India. The label also features the NDC 70377-051-13 and a barcode.*

FDA Label Image

15mg-21-counts (15mg 21 Counts)

Label for Lenalidomide Capsules 15 mg by Biocon Pharma Inc. The label states each capsule contains 15 mg of Lenalidomide and includes a warning about potential human birth defects. The package contains 21 capsules and is marked for prescription use only, with storage instructions and child-resistant packaging noted.*

FDA Label Image

25mg-21-counts (25mg 21 Counts)

Lenalidomide Capsules 25 mg label showing the human prescription drug in capsule form. The label indicates a package of 21 capsules, manufactured by Biocon Pharma Inc. and Biocon Pharma Limited. It includes storage instructions, a warning about potential birth defects, and the National Drug Code (NDC) 70377-054-11.*

FDA Label Image

5mg-28-counts (5mg 28 Counts)

Label for Lenalidomide Capsules 5 mg, an oral prescription drug by Biocon Pharma Inc. The package contains 28 capsules. The label includes usage warnings, storage instructions, and manufacturer information for Biocon Pharma Limited, Bengaluru, India.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of lenalidomide, depicting its molecular framework with key functional groups including an amino group and several carbonyl groups.*

FDA Label Image

Container-2.5mg-28's (Container 2.5mg 28s)

Packaging label for Lenalidomide Capsules 2.5 mg by Biocon Pharma Inc. The label shows the NDC 70377-049-13 and indicates a 28-capsule count. It includes warnings about potential human birth defects, storage instructions, and manufacturer details for Biocon Pharma Inc., Iselin, NJ, and Biocon Pharma Limited, Bengaluru, India. The label also notes the package is child-resistant.*

FDA Label Image

Container-20-mg-21's (Container 20 mg 21s)

Packaging label for Lenalidomide Capsules, 20 mg strength, containing 21 capsules. The label shows the NDC number 70377-053-11 and includes a warning about potential human birth defects. Manufactured by Biocon Pharma Inc., with manufacturing location in Bengaluru, India. Storage instructions and usual dosage guidance are also visible on the label.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve depicting progression-free survival (months) against survival probability (%) for three treatment groups: Rd Continuous (blue solid line), Rd18 (green dashed line), and MPT (red dotted line). The chart includes hazard ratios, confidence intervals, and a logrank p-value. A table below shows the number of subjects at risk over time for each group.*

FDA Label Image

Figure2 (Figure2)

A Kaplan-Meier survival curve showing overall survival probability (%) over time (months) comparing three groups: Rd Continuous, Rd18, and MPT. The plot includes hazard ratios (HR) with 95% confidence intervals for comparisons between groups, and a table displays the number of subjects at risk at various time points for each group. The graph details survival outcomes over approximately 72 months.*

FDA Label Image

Figure3 (Figure3)

A Kaplan-Meier progression-free survival curve comparing Lenalidomide with placebo in months. The y-axis shows survival probability, while the x-axis represents time in months. A table below the chart lists the number of subjects at risk over time for both groups. Event counts for progression-free survival are also noted for Lenalidomide and placebo groups.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier curve chart showing progression-free survival probability over months for Lenalidomide versus placebo. The blue solid line represents Lenalidomide with higher survival probability compared to the red dashed placebo line. The x-axis shows time in months up to 108, and the y-axis shows survival probability from 0 to 1. Below are tables with the number of subjects at risk and progression-free survival events for each group.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve comparing progression-free survival over time (in months) between Lenalidomide/Dexamethasone and Placebo/Dexamethasone treatment groups. The y-axis shows the proportion of subjects, and the graph includes a hazard ratio (HR) with confidence interval and a p-value for statistical significance.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier survival curve graph showing the proportion of subjects over time to progression in months. Two lines represent treatment groups: lenalidomide/Dex in blue and placebo/Dex in black. The graph includes hazard ratio (HR) and p-value statistics for comparison.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier survival curve chart depicting progression-free survival (in months) versus survival probability for two groups: one treated with Rituximab plus Lenalidomide (blue line) and the other with Rituximab plus placebo (red line). The chart includes a risk table showing the number of subjects at risk over time and reports a hazard ratio (HR) with 95% confidence interval and log-rank p-value below 0.0001 indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.